THE WOODLANDS, Texas, Sept. 12, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it believes that enough patients have enrolled in each of its three ongoing Androxal studies to provide statistically meaningful results for each trial. The Company expects to report top-line data for the three trials at the end of 2011. The three Androxal clinical studies are ZA-202, ZA-203 and ZA-204.
